InterCure Ltd.

InterCure Ltd., operating as Canndoc, has secured NIS 22 million, approximately US$7.4 million, through a private placement to support recovery efforts, expand production capacity, and pursue growth in Israel, Germany, and other regulated medical cannabis markets. The financing includes commitments from key shareholders including CEO Alexander Rabinovich and pharma-focused hedge fund Bennu Pharma Fund Ltd., managed by Ori Hershkovitz, and could reach up to NIS 54 million if all warrants are exercised. Under the terms, the company will issue 7,895,143 ordinary shares at NIS 2.75 per share, a premium to the NIS 2.69 closing price on the Tel Aviv Stock Exchange as of June 17, 2026, with investors also receiving warrants to purchase an additional 7,895,143 shares at NIS 4.125 per share, a 53% premium, exercisable for five years. The placement remains subject to definitive documentation and shareholder approval for Rabinovich's participation, and all securities will be subject to transfer restrictions. Proceeds will help expand the Nir Oz facility, meet rising demand, and accelerate global expansion, while expected war-related damage compensation and the new funding aim to strengthen the balance sheet and support a return to sustainable growth and profitability.

InterCure has signed a binding term sheet for a private placement initially raising NIS 22 million, with potential total proceeds of up to NIS 54 million if all warrants are exercised. The financing is backed by existing and new investors, including CEO Alexander Rabinovich and Bennu Pharma Fund. InterCure will issue approximately 7.9 million ordinary shares at NIS 2.75 per share, and investors will receive warrants to purchase up to an additional 7.9 million shares at NIS 4.125 per share, a roughly 53% premium to the reference closing price. The warrants remain exercisable for five years from issuance.